Revolutionary downstream bioconjugation method under development12 Feb 2018
New manufacturing paradigm will save 25% of total costs and the need for proteinaceous A & G resins.
ADC Biotechnology is developing a revolutionary, ‘downstream bioconjugation’ method that will present a new paradigm in Antibody Drug Conjugate (ADC) development and manufacturing. In contrast to the existing approaches – which undertake bioconjugation after both the mAb and cytotoxic have been manufactured – this new approach moves the conjugation step into the later stages of the downstream processing (DSP), with conjugation and antibody purification carried out concurrently.
“The major benefit, and the reason this approach will prove so disruptive, is that it will save several months of manufacturing time and up to 25% of the overall costs. But it will require much of the industry, with its current ingrained manufacturing methods, to reevaluate exactly how it structures the supply chain that often uses three CMOs,” commented Charlie Johnson, CEO of ADC Bio.
Using this ‘downstream bioconjugation’ approach, potentially means less time at the antibody manufacturer (i.e., less time in traditional downstream processing), with the remaining downstream processing and conjugation service both transferring to the bioconjugation CMO. The result is a refined, simpler and much more efficient system – saving up to 3 months of development time and resources plus creating large cost savings.
Under the company’s new process, the starting point for the conjugation will no longer be post-creation of purified antibodies and will instead begin with antibody supernatants. This persuasive approach forgoes the need for extensive chromatographic purification techniques to deliver purified antibody.
The company’s groundbreaking production technique – yet to be formally named –also removes the need for expensive Protein A resins, replacing them with capture resins that are at the heart of the company’s core ‘Lock-Release’ technology. In ADC manufacturing, the Protein A capture step is the most costly in downstream processing, delivering semi-purified antibody. Now, starting from antibody supernatant, ADC Bio’s unique approach will see their patented ‘Lock-Release’ technology facilitate both the antibody capture step and subsequent conjugation to the ADC payload – essentially replacing the Protein A resin and assembling the ADC in an efficient manner. The subsequent viral inactivation, removal and polishing will then occur post-conjugation.
The benefits of eliminating the need for proteinaceous A & G resins extends beyond substantial cost savings. Incidental leaching of these proteins from their purification media increases the impurities in a biopharmaceutical drug product – all of which have to be removed in subsequent chromatography polishing steps before an antibody can be used for any therapeutic application. Moreover, Protein A is known to cause immunogenic responses in humans and has proven toxic in a number of clinical studies – thus its removal is mandatory.
Johnson added: “In essence, we are telescoping antibody DSP and conjugation, providing just one set of analytical development and release processes, whilst bringing in the use of much more cost effective and safer resins. We have already successfully piloted our new development process in a number of applications. As the next step, we have just launched our Specialist Process Innovation Group – which will be responsible for fostering all further technological innovations moving forwards – with its first project being to validate our new downstream conjugation approach over the course of the next 18 months.”
Allergan to establish R&D presence in Cambridge, Massachusetts
10 Jan 2019
The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.Read more
Expedeon signs supply and license agreement for is Lightning-Link technology
9 Jan 2019
The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.Read more
Lilly to bag Loxo Oncology for $8 billion
8 Jan 2019
Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.Read more
Catalent to double its commercial biomanufacturing capacity
7 Jan 2019
The $200-million expansion will support customers’ development programs and commercial launches.Read more
BMS and Celgene merge to create premier innovative biopharma company
3 Jan 2019
Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.Read more
Cambrex completes acquisition of Avista Pharma Solutions
2 Jan 2019
Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.Read more
Novartis offers to acquire CellforCure
1 Jan 2019
Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.Read more
BMS receives offer from Taisho to purchase UPSA
30 Dec 2018
The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.Read more
Recipharm to potentially end operations in Ashton-under-Lyne facility
24 Dec 2018
The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.Read more
An increased risk of a hard or ‘no deal Brexit?
24 Dec 2018
A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation